Emil Behring's medical culture: from disinfection to serotherapy.
作者信息
Simon Jonathan
机构信息
LIRDHIST, Université Lyon 1 F-69622 Villeurbanne Cedex.
出版信息
Med Hist. 2007 Apr;51(2):201-18. doi: 10.1017/s0025727300001198.
Abstract
摘要
相似文献
1
Emil Behring's medical culture: from disinfection to serotherapy.埃米尔·贝林的医学文化：从消毒到血清疗法。
Med Hist. 2007 Apr;51(2):201-18. doi: 10.1017/s0025727300001198.
2
[Behring's personal papers--Behring's lives].[贝林的私人文件——贝林的人生]
Ber Wiss. 2014 Sep;37(3):216-39. doi: 10.1002/bewi.201401680.
3
Contribution of physiologists to the identification of the humoral component of immunity in the 19th century.19世纪生理学家对免疫体液成分识别的贡献。
MAbs. 2017 Jul;9(5):774-780. doi: 10.1080/19420862.2017.1325051. Epub 2017 May 30.
4
[Protecting oneself against contagious diseases: preparing the municipal disinfection service of Turin (19th, 20th centuries)].
Rev Soc Fr Hist Hop. 2008 Dec(Spec No. 131-132):70-4.
5
[Serum therapy--Emil von Behring and the beginnings of research in immunity].[血清疗法——埃米尔·冯·贝林与免疫研究的开端]
Dtsch Med Wochenschr. 1999 Nov 5;124(44):1321-2. doi: 10.1055/s-0029-1233195.
6
[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries].
Rev Prat. 2012 Oct;62(8):1177-81.
7
[Disinfection in Milan at the beginning of XXth century].
Med Secoli. 2011;23(2):495-509.
8
[75 years of serotherapy].
Orv Hetil. 1967 Jan 29;108(5):222-6.
9
10
[Thirty years of disinfection 1955-1985].[消毒三十年（1955 - 1985）]
Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med. 1987 May;184(2):95-107.
引用本文的文献
1
Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.埃博拉病毒病的治疗：从血清疗法到单克隆抗体的应用。
Antibodies (Basel). 2025 Mar 5;14(1):22. doi: 10.3390/antib14010022.
2
Using Nobel Prize case-based learning in Medical Immunology to cultivate critical thinking dispositions for medical undergraduates.运用诺贝尔生理学或医学奖案例式学习培养医学本科生的批判性思维素养。
BMC Med Educ. 2024 Oct 25;24(1):1213. doi: 10.1186/s12909-024-06155-x.
3
The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.恢复期血浆和免疫球蛋白在 COVID-19 大流行中的作用，包括对未来准备工作的影响。
Front Immunol. 2024 Sep 9;15:1448720. doi: 10.3389/fimmu.2024.1448720. eCollection 2024.
4
COVID-19: The question of genetic diversity and therapeutic intervention approaches.新冠病毒：基因多样性与治疗干预方法问题
Genet Mol Biol. 2022 Apr 8;44(1 Suppl 1):e20200452. doi: 10.1590/1678-4685-GMB-2020-0452. eCollection 2021.
5
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.丝状病毒中和抗体：作用机制与治疗应用
Pathogens. 2021 Sep 16;10(9):1201. doi: 10.3390/pathogens10091201.
6
Lassa Virus Treatment Options.拉沙病毒的治疗选择。
Microorganisms. 2021 Apr 7;9(4):772. doi: 10.3390/microorganisms9040772.
7
Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine.免疫球蛋白G2抗体作为新冠疫苗的潜在靶点
Immunotargets Ther. 2020 Sep 29;9:143-149. doi: 10.2147/ITT.S274746. eCollection 2020.
8
The true historical origin of convalescent plasma therapy.恢复期血浆疗法的真实历史起源。
Transfus Apher Sci. 2020 Oct;59(5):102847. doi: 10.1016/j.transci.2020.102847. Epub 2020 Jun 12.
9
A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.关于新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2）治疗方法现代进展的观点。
Eur J Rheumatol. 2020 Aug;7(Suppl 2):S102-S106. doi: 10.5152/eurjrheum.2020.2065. Epub 2020 May 22.
10
Treatment for emerging viruses: Convalescent plasma and COVID-19.新兴病毒的治疗：恢复期血浆与新冠肺炎
Transfus Apher Sci. 2020 Jun;59(3):102790. doi: 10.1016/j.transci.2020.102790. Epub 2020 Apr 20.
Zotero 插件